From a mechanistic standpoint, GLP-1RAs do not interfere with BCR-ABL1 signaling and have not been linked to increased transformation risk in patients with CML. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.